RECURSION PHARMACEUTICALS, INC.

(RXRX)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
9.910 USD   +3.23%
08/02Recursion to Participate in Upcoming Investor Conference
PR
07/21Recursion Pharmaceuticals Obtains European Orphan-Drug Designation for Tumor Syndrome Treatment Candidate
MT
07/21Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Recursion Pharmaceuticals: Q1 Earnings Snapshot

05/10/2022 | 06:03pm EDT

SALT LAKE CITY (AP) _ Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $56 million in its first quarter.

The Salt Lake City-based company said it had a loss of 33 cents per share.

The biotechnology company posted revenue of $5.3 million in the period.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RXRX at https://www.zacks.com/ap/RXRX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about RECURSION PHARMACEUTICALS, INC.
08/02Recursion to Participate in Upcoming Investor Conference
PR
07/21Recursion Pharmaceuticals Obtains European Orphan-Drug Designation for Tumor Syndrome T..
MT
07/21Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatmen..
PR
06/22Berenberg Bank Adjusts Recursion Pharmaceuticals' Price Target to $38 From $36, Maintai..
MT
06/21RECURSION PHARMACEUTICALS : Announces Initiation of Phase 2/3 Trial for the Treatment of N..
PU
06/21RECURSION PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-..
AQ
06/20Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meni..
PR
06/20Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meni..
CI
06/16RECURSION PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (for..
AQ
06/09RECURSION PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Analyst Recommendations on RECURSION PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 44,5 M - -
Net income 2022 -222 M - -
Net cash 2022 264 M - -
P/E ratio 2022 -6,47x
Yield 2022 -
Capitalization 1 705 M 1 705 M -
EV / Sales 2022 32,4x
EV / Sales 2023 26,4x
Nbr of Employees 450
Free-Float 87,8%
Chart RECURSION PHARMACEUTICALS, INC.
Duration : Period :
Recursion Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECURSION PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 9,91 $
Average target price 16,00 $
Spread / Average Target 61,5%
EPS Revisions
Managers and Directors
Chistopher C. Gibson Chief Executive Officer & Director
Tina Larson Chief Operating Officer
Michael Secora Chief Financial Officer
Ramon Martin Chavez Márquez Independent Chairman
Benjamin Mabey Vice President-Software Engineering
Sector and Competitors
1st jan.Capi. (M$)
RECURSION PHARMACEUTICALS, INC.-42.15%1 705
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-19.26%41 093